00 / In brief
Tesamorelin research, one row at a time, by model, endpoint and direction, read 2026-09-05. The strongest study is a single phase 2 randomized open label trial, and a group result is not a reading for any one person. See the approval page, the line between the two objects, and the purity page.
Channel: the molecule on the record
Channel: the molecule on the record. Nothing here is a reading for any person.
01 / What's on this page?
For each study: what it measured, in what model, which direction, and when we read it. The approval has its own page. The strongest study is a single phase 2 randomized open label trial, and a group result is not a reading for any one person.
Channel: the molecule on the record
02 / Which studies are there?
| Record | Year | Model | Measured endpoint | Direction |
|---|---|---|---|---|
| https://pubmed.ncbi.nlm.nih.gov/39813152/ | 2025 | human RCT | neurocognitive performance, waist circumference, mood and daily functioning in people with HIV and abdominal obesity | mixed |
| https://pubmed.ncbi.nlm.nih.gov/21668043/ | 2011 | review | pharmacology, clinical efficacy and tolerability in HIV associated lipodystrophy | review |
| https://pubmed.ncbi.nlm.nih.gov/22050344/ | 2011 | review | efficacy and tolerability in HIV associated central fat accumulation | review |
| https://pubmed.ncbi.nlm.nih.gov/28477736/ | 2017 | review | growth hormone and IGF-1 axis in HIV and therapies targeting it | review |
| https://pubmed.ncbi.nlm.nih.gov/19243281/ | 2009 | review | development and role in HIV related lipodystrophy and other potential indications | review |
| https://pubmed.ncbi.nlm.nih.gov/17086939/ | 2006 | review | development program across the proposed indications | review |
| https://pubmed.ncbi.nlm.nih.gov/41476424/ | 2026 | review | evidence behind peptide therapy in orthopaedics and sports medicine, no supporting orthopaedic evidence for tesamorelin | review |
| https://pubmed.ncbi.nlm.nih.gov/41490200/ | 2026 | review | mechanisms and orthopaedic applications of therapeutic peptides, tesamorelin among growth hormone secretagogues | review |
| https://pubmed.ncbi.nlm.nih.gov/26879649/ | 2016 | animal | detection of growth hormone releasing hormone analogues, tesamorelin named, in plasma | not reported |
| https://pubmed.ncbi.nlm.nih.gov/34665524/ | 2021 | in vitro | metabolism and detection of growth hormone releasing hormone analogues in fortified urine | not reported |
Only the phase 2 trial, pubmed 39813152, reports a human outcome. It was open label and underpowered on cognition. Reviews of pharmacology and tolerability: pubmed 21668043, pubmed 22050344 and pubmed 28477736. Development reviews: pubmed 19243281 and pubmed 17086939. pubmed 41476424 pushes back on orthopaedic claims, and pubmed 41490200 places the molecule among growth hormone secretagogues. Detection studies: pubmed 26879649 in plasma and pubmed 34665524 in fortified urine. They show detection methods exist, not any sport classification. See where the approval was read.
Channel: the molecule on the record
03 / Which trials are registered?
| Record | Status | Phase | Population on the register |
|---|---|---|---|
| https://clinicaltrials.gov/study/NCT00123253 | completed | phase 3 | HIV associated lipodystrophy |
| https://clinicaltrials.gov/study/NCT00608023 | completed | phase 3 | HIV associated lipodystrophy, an extension record |
| https://clinicaltrials.gov/study/NCT01264497 | completed | phase 2 | stable type 2 diabetes, a safety record |
| https://clinicaltrials.gov/study/NCT02572323 | completed | phase 2 | cognition in aging people with HIV |
| https://clinicaltrials.gov/study/NCT00257712 | completed | phase 2 | memory and aging |
| https://clinicaltrials.gov/study/NCT02196831 | completed | not applicable | liver fat in HIV |
| https://clinicaltrials.gov/study/NCT00795210 | completed | not applicable | short term growth hormone in people with HIV |
| https://clinicaltrials.gov/study/NCT00850564 | completed | not applicable | short term growth hormone releasing hormone in healthy men |
| https://clinicaltrials.gov/study/NCT02931474 | withdrawn | phase 2 | sleep and insomnia after traumatic brain injury in service members |
| https://clinicaltrials.gov/study/NCT01579695 | terminated | none listed | a long term observational registry in people with HIV |
Two completed phase 3 trials in HIV associated lipodystrophy: NCT00123253 and NCT00608023. Others: NCT01264497 in stable type 2 diabetes, NCT02572323 and NCT00257712 in cognition and memory, NCT02196831 in liver fat, NCT00795210 in short term growth hormone in people with HIV, and NCT00850564 in healthy men. One was withdrawn, NCT02931474, and one long term observational registry was terminated, NCT01579695. None has a result in our sources.
Channel: the molecule on the record
What does Peptara Labs sell?
Links to Peptara Labs are affiliate links, and we may earn a commission when you buy through them.
It lists a catalogue of research grade peptides and publishes prices on its own pages, which we don't repeat. It ships research grade material, a different thing from the approved medicine these studies are about. Its tesamorelin listing at Peptara Labs is one of them.
Channel: research material
04 / How did we read the studies?
Each study goes into one of four groups: the approved medicine, the molecule on the record, the research material, or not connected. Each row comes from one named record with its read date: research read 2026-09-05, vendor facts read 2026-09-07. Record types: the approved label note in the pack, the human trial, the review, the registered study with no result, the vendor document, and none. We never put an amount, frequency, route or unit in a cell, so the direction column is a word, never a size. Corrections need a record, sent via the contact page. We don't connect the medicine to the research material: see the object the record does not connect.
Channel: not connected
Does Peptara Labs make medical claims about these compounds?
No. It frames what it sells as research grade material for lab use, and says plainly that it isn't a medical provider and guarantees no health result. So nothing these studies report becomes advice for a person here.
Channel: research material
05 / What are the limits here?
We report what a record says and stop there. Every study comes with its model and the direction it found. Every vendor claim is labelled as the vendor's. The approved medicine and the research material stay apart, and nothing crosses between them. We rate no one, promise nothing, and give no steps to follow.
Channel: not connected
Who tests Peptara Labs peptides?
It names Titreon Analytical as its testing lab, a separate laboratory whose quality system is aligned to ISO/IEC 17025:2017 and not itself accredited. That's a vendor claim about the research material, separate from the studies above.
Channel: research material